美国 · SEC FORM 4
NEXGEL, INC.
NXGL · Nasdaq · CIK 0001468929 · Healthcare · Medical Instruments & Supplies
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
9 同一窗口内观察到的 Form 4 交易行
9 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-11-20 · ZELDIS JEROME B.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 322,449
- 上期报告
- 197,339
- 日均成交量
- 588,839
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-11-20 | glassman steven mark | 买入 (P) | Common Stock | 9,090 | USD 2.75 | USD 24,998 | SEC 申报 ↗ |
| 2024-11-20 | ZELDIS JEROME B | 买入 (P) | Common Stock | 3,636 | USD 2.75 | USD 9,999 | SEC 申报 ↗ |
| 2024-11-20 | Stein John Nachum | 买入 (P) | Common Stock | 3,636 | USD 2.75 | USD 9,999 | SEC 申报 ↗ |
| 2024-11-20 | Levy Adam R. | 买入 (P) | Common Stock | 3,636 | USD 2.75 | USD 9,999 | SEC 申报 ↗ |
| 2024-11-20 | Henry Scott Robert | 买入 (P) | Common Stock | 1,818 | USD 2.75 | USD 5,000 | SEC 申报 ↗ |
| 2024-11-20 | Drapczuk Adam E III | 买入 (P) | Common Stock | 17,500 | USD 2.75 | USD 48,125 | SEC 申报 ↗ |
| 2024-08-23 | Stein John Nachum | 买入 (P) | Common Stock | 10,000 | USD 2.50 | USD 25,000 | SEC 申报 ↗ |
| 2024-08-23 | glassman steven mark | 买入 (P) | Common Stock | 10,000 | USD 2.50 | USD 25,000 | SEC 申报 ↗ |
| 2024-08-23 | ZELDIS JEROME B | 买入 (P) | Common Stock | 10,000 | USD 2.50 | USD 25,000 | SEC 申报 ↗ |
| 2024-08-23 | Henry Scott Robert | 买入 (P) | Common Stock | 10,000 | USD 2.50 | USD 25,000 | SEC 申报 ↗ |
| 2024-08-23 | Drapczuk Adam E III | 买入 (P) | Common Stock | 10,000 | USD 2.50 | USD 25,000 | SEC 申报 ↗ |
| 2024-03-01 | glassman steven mark | 买入 (P) | Common Stock | 11,848 | USD 2.11 | USD 24,999 | SEC 申报 ↗ |
| 2024-03-01 | Henry Scott Robert | 买入 (P) | Common Stock | 23,697 | USD 2.11 | USD 50,001 | SEC 申报 ↗ |
| 2024-03-01 | Drapczuk Adam E III | 买入 (P) | Common Stock | 47,394 | USD 2.11 | USD 100,001 | SEC 申报 ↗ |
| 2023-12-22 | glassman steven mark | 买入 (P) | Common Stock | 3,885 | USD 2.20 | USD 8,547 | SEC 申报 ↗ |
Form 4 申报证据
12 transaction lines in the latest 365-day window; 106 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-23 | Levy Adam R. | 卖出 (S) | Common Stock | 5,000 | USD 0.59 | USD 2,950 | SEC 申报 ↗ |
| 2026-06-18 | Levy Adam R. | 卖出 (S) | Common Stock | 6,000 | USD 0.59 | USD 3,540 | SEC 申报 ↗ |
| 2026-06-11 | Levy Adam R. | 卖出 (S) | Common Stock | 3,000 | USD 0.61 | USD 1,830 | SEC 申报 ↗ |
展开近期 Form 4 证据 (12 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-23 | Levy Adam R. | 卖出 (S) | Common Stock | 5,000 | USD 0.59 | USD 2,950 | SEC 申报 ↗ |
| 2026-06-18 | Levy Adam R. | 卖出 (S) | Common Stock | 6,000 | USD 0.59 | USD 3,540 | SEC 申报 ↗ |
| 2026-06-11 | Levy Adam R. | 卖出 (S) | Common Stock | 3,000 | USD 0.61 | USD 1,830 | SEC 申报 ↗ |
| 2026-06-08 | Levy Adam R. | 卖出 (S) | Common Stock | 3,000 | USD 0.55 | USD 1,650 | SEC 申报 ↗ |
| 2026-06-04 | Levy Adam R. | 卖出 (S) | Common Stock | 3,000 | USD 0.59 | USD 1,770 | SEC 申报 ↗ |
| 2026-06-01 | Levy Adam R. | 卖出 (S) | Common Stock | 2,000 | USD 0.59 | USD 1,180 | SEC 申报 ↗ |
| 2026-05-29 | Levy Adam R. | 卖出 (S) | Common Stock | 3,000 | USD 0.60 | USD 1,800 | SEC 申报 ↗ |
| 2026-05-28 | Levy Adam R. | 卖出 (S) | Common Stock | 7,000 | USD 0.61 | USD 4,270 | SEC 申报 ↗ |
| 2026-05-27 | Levy Adam R. | 卖出 (S) | Common Stock | 3,000 | USD 0.60 | USD 1,800 | SEC 申报 ↗ |
| 2025-12-24 | Levy Adam R. | 卖出 (S) | Common Stock | 4,000 | USD 1.57 | USD 6,280 | SEC 申报 ↗ |
| 2025-12-22 | Levy Adam R. | 卖出 (S) | Common Stock | 6,000 | USD 1.61 | USD 9,660 | SEC 申报 ↗ |
| 2025-11-06 | Levy Adam R. | 卖出 (S) | Common Stock | 4,000 | USD 2.52 | USD 10,080 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NXGL |
| CIK | 0001468929 |
| 行业 | Healthcare |
| 细分行业 | Medical Instruments & Supplies Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 106 transaction lines from 2020-02-17 to 2026-06-23 62 P purchase lines · 35 S sale lines · 9 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.